文献速递血栓与止血

靶向抗凝血酶的siRNA疗法fitusiran治疗伴抑制物血友病A或B的1期抑制物队列结果

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
PubMed 文献 · J Thromb Haemost · 2021-05-18

fitusiran是一种降低抗凝血酶产生的小干扰RNA研究性疗法,用于伴或不伴抑制物的血友病A或B患者。本开放标签1期D部分研究纳入17例伴抑制物的中重度血友病A或B男性,每月皮下注射fitusiran 50 mg(n=6)或80 mg(n=11)共三次,随访至112天。最常见不良事件为注射部位红斑(n=8),未报告血栓事件;抗凝血酶活性最低点较基线分别下降82.0%(2.2)和87.4%(0.7),并伴凝血酶生成增加;11/17(64.7%)参与者在观察期(平均69.4天,标准差16.3)内无出血。

要点

  • fitusiran每月皮下注射总体耐受良好,最常见不良事件为注射部位红斑。
  • 抗凝血酶活性最低点较基线下降82.0%(50 mg组)和87.4%(80 mg组),伴凝血酶生成增加。
  • 11/17(64.7%)参与者在观察期内无出血,生活质量评分改善提示有临床意义。

核心结论

  • 每月fitusiran总体耐受良好,降低抗凝血酶水平并改善凝血酶生成。
  • 初步结果提示每月fitusiran可能减少伴抑制物血友病A或B患者的出血发作并改善生活质量。

研究设计与样本

  • 开放标签1期D部分研究,纳入17例伴抑制物的中重度血友病A或B男性。
  • 受试者接受三次每月一次皮下注射fitusiran 50 mg(n=6)或80 mg(n=11),随访至112天。

主要发现

  • 最常见不良事件为注射部位红斑(n=8),未报告血栓事件。
  • 抗凝血酶活性最低点较基线平均(均值标准误)下降:50 mg组82.0%(2.2),80 mg组87.4%(0.7)。
  • 抗凝血酶降低与凝血酶生成增加相关。
  • 11/17(64.7%)参与者在观察期(平均69.4天,标准差16.3)内无出血。
  • 成人血友病生活质量问卷总分变化-9.2(2.9)、身体健康领域变化-12.3(3.9),提示有临床意义改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors. OBJECTIVES: To evaluate the safety and efficacy of fitusiran treatment for people with moderate/severe hemophilia A or B with inhibitors. PATIENTS/METHODS: In this open-label phase 1, part D study, 17 males with hemophilia A or B with inhibitors received three once-monthly subcutaneous injections of fitusiran 50 mg (n = 6) or 80 mg (n = 11); followed for up to 112 days. Endpoints included safety (primary), pharmacokinetics/pharmacodynamics (secondary), annualized bleeding rate, and patient-reported outcomes (exploratory). RESULTS: The most common adverse event was injection site erythema (n = 8). No thrombotic events were reported. At nadir, mean (standard error of the mean [SEM]) antithrombin activity decreased from baseline by 82.0% (2.2) and 87.4% (0.7) in the 50 mg and 80 mg groups, respectively. Antithrombin reduction was associated with increased thrombin generation. 11/17 (64.7%) participants had no bleeds during the observation period (mean [standard deviation] 69.4 [16.3] days). Mean (SEM) changes from baseline in Haemophilia Quality of Life Questionnaire for Adults total (-9.2 [2.9]) and physical health (-12.3 [3.9]) domain scores suggested clinically meaningful improvement. CONCLUSIONS: Monthly fitusiran was generally well tolerated, lowered antithrombin levels from baseline, and resulted in improved thrombin generation. These preliminary results suggest that monthly fitusiran treatment may reduce bleeding episodes and improve quality of life in participants with hemophilia A or B with inhibitors.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021. PMID: 33587824. doi:10.1111/jth.15270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。